TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05201417

Intervention type: OTHER
Group type: OTHER
Intervention: adapted physical activity
Description: The adapted physical activity will be administered remotely through the whatsApp or YouTube application. Two sessions will be done per week: Wednesday and Sunday. Walking seems to be appropriate for all participants We will account for 24 APA sessions. We will leverage the Step Tracker phone app and pedometer to get the number of steps done, number of calories spent, Workout duration and distance walked per participant per APA session; this data will be collected weekly (after every two sessions)
Study: NCT00533988

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Antimicrobial impregnated catheter (5593)
Description: Comparison of 14-day placement of a standard triple lumen (ARROW Standard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US) versus an antimicrobial impregnated catheter (Chlorhexidine-silver sulfadiazine)(ARROWgard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US)
Study: NCT06736353

Intervention type: DRUG
Intervention: Beta Blocker Therapy or No Therapy (Control)
Description: Beta blocker therapy or no Beta blocker therapy initiated after type 2 myocardial infarction

Intervention type: DRUG
Intervention: RAAS blocker Therapy or No therapy (Control)
Description: RAAS blocker therapy or no RAAS blocker therapy initiated after type 2 myocardial infarction

Intervention type: DRUG
Intervention: Statin Therapy or No Therapy (Control)
Description: Statin therapy or no Statin therapy initiated after type 2 myocardial infarction

Intervention type: DRUG
Intervention: Single Antiplatelet Therapy or No Therapy (Control)
Description: Single Antiplatelet Therapy or no Single Antiplatelet Therapy therapy initiated after type 2 myocardial infarction

Intervention type: DRUG
Intervention: Dual Antiplatelet Therapy or No Therapy (Control)
Description: Dual Antiplatelet Therapy or no Dual Antiplatelet Therapy initiated after type 2 myocardial infarction
Study: NCT03863743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated care pathway
Description: Incidence of POUR after undergoing total hip or knee replacement and integrated care pathway will be evaluated.

Intervention type: OTHER
Group type: OTHER
Intervention: physician's standard of care
Description: Incidence of POUR will be evaluated in standard of care treatment.
Study: NCT01813032

Intervention type: PROCEDURE
Intervention: Forearm Vascular Study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).

Intervention type: PROCEDURE
Intervention: Forearm Vascular Study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).

Intervention type: PROCEDURE
Intervention: Badimon Chamber
Description: Ex-vivo assessment of thrombus formation using the Badimon Chamber

Intervention type: PROCEDURE
Intervention: Badimon Chamber
Description: Ex-vivo assessment of thrombus formation using the Badimon Chamber
Study: NCT02585037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping® bandage
Description: The Kinesio Taping® bandage will be applied in an I format in the wrist flexor muscles of a dominant and non-dominant limb in G1 and G2 groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping® bandage
Description: The Kinesio Taping® bandage will be applied in an I format in the wrist flexor muscles of a dominant and non-dominant limb in G1 and G2 groups.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dynamometer Jamar® pressure
Description: The Jamar® dynamometer will be adjusted to the second position for measurement of maximal voluntary strength of handgrip. A muscle contraction period of three seconds will be performed in order to record handgrip strength.
Study: NCT00881660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goldballoon Detachable Balloon and delivery microcatheter
Description: Between 27+0/7 - 29+ 6/7 weeks gestation for severe CDH and can be as early as 22+0/7 weeks gestational age for those deemed as extremely severe cases of CDH, placement of the Goldvalve detachable balloon. Balloon retrieval will be planned for between 32+0/7 and 34+6/7 weeks or no longer than 10 weeks after balloon placement at the discretion of the FETO center.
Study: NCT01116050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 5 tablets of 200 microgram geach intra rectal by opaque introducer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 tablets in opque introducer
Study: NCT02029976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SNAPSHOT (Student, Nurses and Parents Seeking Healthy Options Together)
Description: attention control condition after school weight management program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mailed monthly newsletters
Description: Newsletters
Study: NCT03027167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: (Post- discharge) Mechanical Compression Device
Study: NCT02149641

Intervention type: RADIATION
Intervention: Intensity modulated radiotherapy with chemotherapy
Study: NCT03109431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Level 1
Description: Youth will receive 1-5 text messages per day for at least 12 months. Banks of about 750 messages (70-120 messages per domain) focus on the HIV Treatment Continuum, with messages focused on dedicated to healthcare, wellness, sexual health, drug use and medication reminders. Youth will be able to choose the time and frequency that they receive daily texts. Preferences for the timing and type of messages can be updated at 4-month assessment points.~Youth will complete weekly monitoring surveys by text message. The survey will cover six domains related to the HIV Treatment Continuum. If YLH do not respond to the text, reminder messages will be sent to the youth. After three days of non-response a follow-up call by an interviewer will be made to the YLH.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Level 1
Description: Youth will receive 1-5 text messages per day for at least 12 months. Banks of about 750 messages (70-120 messages per domain) focus on the HIV Treatment Continuum, with messages focused on dedicated to healthcare, wellness, sexual health, drug use and medication reminders. Youth will be able to choose the time and frequency that they receive daily texts. Preferences for the timing and type of messages can be updated at 4-month assessment points.~Youth will complete weekly monitoring surveys by text message. The survey will cover six domains related to the HIV Treatment Continuum. If YLH do not respond to the text, reminder messages will be sent to the youth. After three days of non-response a follow-up call by an interviewer will be made to the YLH.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Level 2
Description: Youth will be enrolled in online, private discussion groups.~Peer Support will be offered by fellow participants and/or Youth Advisory Board members that have been trained in basic information on HIV, STI, drug use, mental health, homelessness, and stigma; using social media to create wall posts and use chat functions; and, how to initiate conversations on sensitive topics. By posting and responding to messages, Peer Supporters will encourage and broadly guide conversation related to the HIV Prevention Continuum, and other relevant topics.~Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Level 3
Description: Youth will have be assigned to a Coach trained in a strengths--based Coaching intervention, as well as common foundational theory, principles and skills used in adolescent HIV Evidence-Based Interventions (EBI). Youth preferences will drive the intervention delivery - whether in-person, electronically via the phone, email, text message, social media private messaging.
Study: NCT02031679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: AZD1981 is an oral, potent, selective, reversible antagonist of CRTh2 (Chemoattractant Receptor Homologous Molecule expressed on Th2 cells).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic AZD1981 10 mg tablet
Study: NCT02585037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamometer Jamar® pressure
Description: The Jamar® dynamometer will be adjusted to the second position for measurement of maximal voluntary strength of handgrip. A muscle contraction period of three seconds will be performed in order to record handgrip strength.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamometer Jamar® pressure
Description: The Jamar® dynamometer will be adjusted to the second position for measurement of maximal voluntary strength of handgrip. A muscle contraction period of three seconds will be performed in order to record handgrip strength.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the control group (G3) the Kinesio Taping® bandage will be placed from the lateral extremity to the medial axis.
Study: NCT03376841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc
Description: 1 tablet; single-dose oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc
Description: 1 tablet; single-dose oral administration
Study: NCT02127905

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CD34+ selected cells
Description: Compassionate treatment of Fanconi Anemia patients with unrelated bone marrow or peripheral blood HSCT followed by the infusion of CD34+ selected cells using CliniMACS
Study: NCT05438615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corneal Refractive Therapy-spherical
Description: A comparison of two different designs of Corneal Refractive Therapy contact lenses will be done. Each will be worn for two weeks. The sponsor will mask which lens will be first or second in the trial.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corneal Refractive Therapy-aspherical
Description: A comparison of two different designs of Corneal Refractive Therapy contact lenses will be done. Each will be worn for two weeks. The sponsor will mask which lens will be first or second in the trial.
Study: NCT03197285

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined Physiotherapy Protocol
Description: Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful).
Study: NCT00061620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezacitabine (FMdC)
Description: 7.5 mg/m2 bolus infusion daily x 5
Study: NCT00556348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 1.25mg
Study: NCT03820531

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Next Generation Sequencing
Description: DNA Mutational Analysis in pancreas cyst fluid concerning KRAS/GNAS-mutations and mutations in tumor supressor genes

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CEA and lipase
Description: Measuring CEA and lipase level in pancreas cyst fluid:~CEA \> 192 ng/ml and lipase \> 200 U/l = mucinous cyst

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cytology
Description: Cytology in pancreas cyst fluid:~mucinous versus non-mucinous cyst; LGD versus HGD/Carcinoma

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Histology of resected pancreas cyst
Description: Histology of resected pancreas cyst concerning mucinous versus non-mucinous cyst, IPMN versus non-IPMN and LGD versus HGD/Carcinoma
Study: NCT01463917

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic solution
Description: Use of Hypertonic solution 4 ml/Kg during left marginal branch CABG surgery.
Study: NCT03135392

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breast Reconstruction with Artificial Implant
Description: Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with artificial implants

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Breast Reconstruction
Description: Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with the patient's own tissue
Study: NCT02737046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Belinostat will be administered as 1,000 mg/m2 IV infusion over 30 minutes on Days 1- 5 every 21 days (Exception as per FDA-approved Package Insert: In patients known to be homozygous for the UGT1A1\*28 allele, the starting belinostat dose must be 750mg/m2) for up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Zidovudine shall be administered in the outpatient setting as 300 mg tablets orally (PO), three times daily (TID) for 21 days on cycles 1 to 8, followed by maintenance therapy (+/- IFN-alfa) up to the end of Month 12.
Study: NCT03135392

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Breast Reconstruction
Description: Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with the patient's own tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurotization
Description: Nerve will be reconstructed during autologous breast tissue reconstruction
Study: NCT04785612

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF
Description: A single dose of 120 mcg RSVpreF for intramuscular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single Placebo dose for intramuscular injection to match experimental vaccine
Study: NCT04360304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echocardiographic exam
Description: An echocardiographic exam is realised after inclusion, measuring especially :~* LVOT VTI~* Respiratory variation of inferior veina cava diameter For theses two measurements, the manual method is first recorded, and then the automated one is done.~For patients that need fluid resuscitation of at least 250mL in less than 10minutes (indication at the discretion of the physician in charge of the patient), a second echocardiography is done according to the same protocol described before.
Study: NCT00659295

Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of a normal clinical practice.

Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of a normal clinical practice.
Study: NCT02456584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMPA 150
Description: injectable contraceptive

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMPA 300
Description: injectable contraceptive

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMPA 104
Description: injectable contraceptive
Study: NCT01059448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 827
Description: AMG 827 210 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 827
Description: AMG 827 210 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 827
Description: AMG 827 210 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 827
Description: AMG 827 210 mg
Study: NCT01390389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: Single pill consists of 400 mg and is delivered PO.~CoQ10 dosing guidelines:~* Visit 1 (baseline) start at 400mg once a day for two weeks~* Visit 2 (within 7 days of baseline visit) increase to 800 mg once a day for two weeks~The dosage of CoQ10 can be titrated in a more gradual manner depending on clinical response and tolerability of the medication, but cannot be titrated any more rapidly than the schedule above.
Study: NCT00510705

Intervention type: OTHER
Group type: OTHER
Intervention: exercise training
Description: physical exercise training on a bicycle ergometer daily for 4 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: exercise training + metformin
Description: physical exercise training on a bicycle ergometer + metformin (2 x 850 mg) daily for 4 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: exercise training + glitazone
Description: physical exercise training on a bicycle ergometer + glitazone daily for 4 weeks
Study: NCT00778830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m\^2) biweekly on Day 1 of 14 days treatment cycle until disease progression, occurrence of unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m\^2) biweekly on Day 1 of 14 days treatment cycle until disease progression, occurrence of unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Irinotecan will be administered intravenously at a dose of 180 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2 (L-form) and 5-fluorouracil will be administered intravenously at a dose of 400 mg/m\^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m\^2 given biweekly until disease progression, death, or consent withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Oxaliplatin will be administered intravenously at a dose of 100 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2 (L-form) and 5-fluorouracil administration intravenously at a dose of 400 mg/m\^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m\^2 given biweekly until disease progression, death, or consent withdrawal.
Study: NCT00503191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NeuroModulation Technique
Description: NeuroModulation Technique is an informational technique that works by identifying and bringing awareness of the mind-body to incorrect informational states of the nervous system which has led to illness or maladaptive behavior. NeuroModulation Technique then directs the body to correct these information states, thereby helping the nervous system resume more adaptive functioning.
Study: NCT01888094

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound-guided cannulation and examination

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided cannulation and examination
Study: NCT02639377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
Study: NCT02276261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal cuff closure - vertical
Description: Vaginal cuff is closed vertically.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal cuff closure - horizontal
Description: Vaginal cuff is closed horizontally.
Study: NCT03572088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: Terlipressin is a synthetic vasopressin analogue with relative specificity for the splanchnic circulation(Terlipressin was started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Patients received 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
Study: NCT02511522

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Description: Including analgesics, palliative care and/or pain specialist assessment as needed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Including analgesics, palliative care and/or pain specialist assessment as needed

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiation Therapy
Description: 8 Gy in 1 fraction in whole liver or near whole liver. Including anti-emetic pre-medications
Study: NCT06252116

Intervention type: DRUG
Intervention: Pregabalin group
Description: Pregabalin group

Intervention type: DRUG
Intervention: Duloxetine group
Description: Duloxetine group
Study: NCT01239407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally focused psychiatric consultation
Description: The consultation is comprised of 3 visits:~1a. Psychiatric diagnostic interview, self-rated questionnaires (in-person consultation).~1b. Intervention focused on learning about depression and how to treat it using culturally relevant resources.~2. Follow-up visit two weeks later to go over patients' questions, homework if applicable, and patients' ability to meet the goals outlined in the first visit (in-person or phone visit).~3. 6-month follow up: 6 months after the initial consultation, patients are asked about mental health symptoms and mental health treatment they might be receiving (phone visit unless patient requests in-person).
Study: NCT04047888

Intervention type: OTHER
Intervention: Nutrition-based education on infant feeding and practices as well as Non nutrition-based educational message
Description: 60 minute educational message at each visit
Study: NCT00424008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F) MDI
Description: MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate/salmeterol (F/SC) DPI
Description: Fluticasone propionate 250 mcg and salmeterol 50 mcg fixed dose combination dry powder inhaler taken twice daily for 52 weeks.
Study: NCT00482092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochymal®
Description: Prochymal® IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochymal®
Description: Prochymal® IV infusion